EMA to keep clos­er tabs on sup­plies of all ap­proved Covid-19 vac­cines and ther­a­peu­tics

The Eu­ro­pean Med­i­cines Agency on Wednes­day re­leased a new list of crit­i­cal med­i­cines to bat­tle the on­go­ing pan­dem­ic, which will put the mar­ket au­tho­riza­tion hold­ers for these Covid-19 vac­cines and drugs on the hook for reg­u­lar­ly up­dat­ing the EMA with da­ta on po­ten­tial or ac­tu­al short­ages and avail­able stocks, fore­casts of sup­ply and de­mand.

Eu­ro­pean Mem­ber States al­so will have to pro­vide reg­u­lar re­ports on es­ti­mat­ed de­mand for these crit­i­cal med­i­cines on the na­tion­al lev­el. The list in­cludes vac­cines from Pfiz­er/BioN­Tech, Mod­er­na, No­vavax, J&J, and As­traZeneca, as well as drugs like dex­am­etha­sone, Pfiz­er’s Paxlovid, Gilead’s remde­sivir, and oth­er mon­o­clon­al an­ti­bod­ies from As­traZeneca, Re­gen­eron, Roche and oth­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.